- SAVE THE DATE
Thursday 12 October, London
- SAVE THE DATE
Thursday 12 October. London
Chief Executive, NHS England
Simon is Chief Executive of NHS England, which leads the NHS' work nationally to improve health and ensure high quality care for all. As the NHS Accounting Officer he is also accountable to Parliament for over £100 billion of annual Health Service funding.
Simon joined the NHS through its Graduate Training Scheme in 1988. As a frontline NHS manager he subsequently led acute hospitals, mental health and community services, primary care and health commissioning in the North East of England, London and the South Coast. He also served seven years as the Prime Minister’s Health Adviser at 10 Downing Street, and as policy adviser to successive Health Secretaries at the Department of Health.
Simon also spent a decade working internationally at UnitedHealth Group, including as its Medicare CEO and as president of its global health division, leading health services in the United States, Europe, Brazil, India, China, Africa, and the Middle East.
Simon was born in Birmingham, and was educated at Balliol College, Oxford University; Strathclyde University, Glasgow; and Columbia University, New York where he was Harkness Fellow at the New York City Health Department. He is married with two school-age children, and volunteers as a director of the Commonwealth Fund, a leading international health charity. He has also been a trustee of the Kings Fund and the Nuffield Trust and Visiting Professor at the London School of Economics.
Head of Secretariat, Review on Antimicrobial Resistance and Senior Policy Advisor, HM Treasury
Hala heads the Review team, on secondment from HM Treasury. Before joining the UK civil service, she was an international arbitration lawyer at Skadden, Arps, Slate, Meagher & Flom LLP in New York and London, advising clients in a range of industries including energy, construction and financial services.
Hala studied law in Paris and at Columbia University Law School and public administration at the Kennedy School of Government and the LSE.
Chief Executive Officer, Stratagem IPM
Nicola is Chief Executive Officer of Stratagem Intellectual Property Management Limited which she founded in 1999. At Stratagem, Nicola has pioneered strategic management of IP through her strong commercial experience and belief that IP clients require expert advice as part of an overall defined plan for maximising the value of IP assets.
Nicola is also an accredited mediator providing dispute resolution in the IP and general corporate arenas. Nicola has a joint degree in Biology and Biochemistry and qualified as a UK and European Patent Attorney at the Wellcome Foundation Ltd in 1991.
Chief Executive Officer, BIA
Since his appointment as Chief Executive of the UK Bioindustry Association (BIA) in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors.
Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee. Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations.
An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years.
Aisling Burnand MBE
Chief Executive Officer, Association of Medical Research Charities
Aisling began her career in media relations, working mostly in the private sector. She headed international media relations for Rhône-Poulenc and was a director at the Rowland Company. She joined the UK BioIndustry Association (BIA) as its first director of public affairs in 1998, before becoming chief executive in 2003. At the BIA she championed UK biosciences, leading on issues including regenerative medicine and animals in research. In 2007 Aisling received an MBE for services to science.
She joined Cancer Research UK in 2009, where she was executive director of policy and public affairs. During her tenure the charity secured the implementation of point of sale legislation preventing children from viewing cigarettes in shops, and the Sunbeds Act to protect young people from the dangers of sunbeds.
Since 2012 Aisling has run a coaching practice providing support for senior leaders in business. In addition, Aisling is a trustee for the Campaign for Science and Engineering (CaSE) and a school governor.
Professor Tom Brown
Professor of Nucleic Acid Chemistry,University of Oxford
Tom is Professor of Nucleic Acid Chemistry at Oxford University and a member of the Departments of Chemistry and Oncology. His research interests centre on DNA sequence recognition and applications of DNA and RNA chemistry in biology, diagnostics, forensics and medicine. He is the co-founder of three Biotech companies (Oswel, ATDBio and Primer Design) and has published over 350 research papers and patents.
He has received several awards including the Royal Society of Chemistry (RSC) Josef Loschmidt prize, the RSC award for Nucleic Acid Chemistry and the RSC prize for Interdisciplinary Research. He was Chemistry World entrepreneur of the year for 2014 and BBSRC Commercial Innovator of the Year and overall Innovator of the Year for 2016. Recently he was presented with a lifetime award for external engagement and promoting impact by Oxford University.
Tom is a Fellow of the Royal Society of Edinburgh and a Fellow of the Royal Society of Chemistry. He is President of the Chemistry Biology Interface Division of the RSC and Editor-in-Chief of the RSC Book series on Chemical Biology. He is currently Associate Head of the Chemistry Department at Oxford with responsibility for Research.
Dr Zoë Cattell
Industrial Liaison Marketing Manager, Diamond Light Source
Zoë is the Industrial Liaison Marketing Manager at Diamond Light Source; the UK’s national synchrotron facility located in south Oxfordshire. She has worked at Diamond for over seven years, previously co-ordinating the extensive events programme of workshops and conferences and managing the organisation’s open access programme for publications.
In her capacity as Marketing Manager, Zoë has responsibility for the delivery of all marketing functions, creating and designing publicity material, writing content for the industrial liaison webpages and handling the social media accounts. She co-ordinates all industry associated events and handles business development opportunities.
Zoë’s career started out in the Pharmaceutical Industry working in a sales and marketing capacity for 3M Healthcare. She then spent many years in a highly successful career in pharmaceutical and regional executive recruitment. A scientist by training, Zoë holds a degree in Pharmacology from Leeds University.
International Tax Executive Director, EY
Sarah leads the Life Sciences team within EY UK’s International Tax Services practice. She has been providing tax advice to multinational companies for 18 years and has significant experience advising Pharma and Biotech clients on the corporate tax aspects of investing in the UK, including tax efficient financing, IP centralisation, Patent Box, Diverted Profits Tax, permanent establishment and withholding tax management.
Over the past five years, Sarah has worked closely with policy-makers and the UK tax authorities on the UK’s patent box regime and has assisted clients across the life sciences industry to understand, evaluate and access the regime.
Sarah’s clients range from large pharmaceutical groups to smaller biotech and specialty pharma companies that are pre-launch. She recently spent two years on EY’s Global Desks in New York.
She has published articles in several tax journals and is a regular speaker at tax seminars and conferences. Sarah is a chartered accountant and has a master’s degree in Mathematics from Oxford University.
Director of Research Partnerships, JDRF
Rachel was appointed Director of Research Partnerships at JDRF UK in April 2016. In this role she focuses on identifying and developing strategic opportunities for collaboration in type 1 diabetes research, and facilitating the smooth and effective running of JDRF’s research in the UK.
Rachel is the spokesperson for JDRF UK on research issues. She represents JDRF and people with type 1 diabetes on a number of project groups, and she also acts as a point of liaison for the UK type 1 diabetes research community.
She joined JDRF in 2008 as Research Communication Manager. In this role and following her subsequent promotion to Head of Research Communication, she focused on communicating effectively about JDRF’s research with people affected by type 1 diabetes, policy makers and the general public. She continues to lead this work in her current role.
Dr Rob Cooke
Head of the Biomolecular Structure Department, Heptares Therapeutics
Rob obtained his BSc and PhD (Inorganic Chemistry) from the University of Sydney. He then did post-doc studies with Iain Campbell in the Department of Biochemistry at the University of Oxford, determining solution structures of growth factors by NMR. Rob joined Glaxo to establish protein NMR studies, and while at Glaxo, Glaxo Wellcome and GlaxoSmithKline he led a number of areas including structural biology and biophysics, protein production, analytical chemistry and biochemistry, and computational chemistry.
Rob has also been involved in several external partnerships, including establishing the Structural Genomics Consortium in 2003, chairing the SAB during the first phase of operations, and serving as a Board Director during the second.
Rob joined Heptares Therapeutics in 2011 as Head of Biomolecular Structure, where he is responsible for structural biology and biophysics, computational chemistry and informatics and protein biochemistry, as well as management of external alliances.
Executive Chairman, Eagle Genomics
Anthony is Executive Chairman at Eagle Genomics. As Chairman and CEO, he has built and exited a number of intellectual property rich B2B software companies. In particular, he was responsible for the turnaround, strategic repositioning and sale of private, venture backed communications software company, Psytechnics to US Nasdaq listed NetScout. As CEO, he was responsible for the turnaround, strategic repositioning and sale of Nasdaq and LSE listed network management software company, Orchestream plc. to US Nasdaq listed MetaSolv Software and as Managing Director of MetaSolv, he was responsible for doubling the size of the European business, prior to that company being acquired by Oracle.
In addition to his extensive operational experience, Anthony has occupied every seat at the board table: Chairman, CEO, CFO, NXD and Investor Director (for both public and private companies) and he is uniquely qualified in working with CEO’s and their management teams to meet the most significant challenges that they will encounter on their journey.
In addition to his responsibilities at Eagle Genomics, Anthony is chairman of the Supervisory Board of German headquartered nano-imaging company, JPK Instruments and is adviser to a number of B2B technology companies. He was most recently also active as a private equity investor.
Dr Hazel Ford
Partner, European Patent Attorney, Finnegan
Hazel is a European patent attorney and chartered UK patent attorney. She has extensive experience drafting and prosecuting patent applications at the European Patent Office (EPO), particularly in the field of biotechnology, including antibodies, vaccines, genes and proteins, and pharmaceuticals related to drug formulation, diagnostics, and new administration regimes. She also has experience coordinating patent proceedings internationally.
Hazel has substantial experience with EPO opposition and appeal proceedings and has handled EPO oppositions in technology areas including antibodies, protein and antibody purification, therapeutics, and drug delivery formulations.
Hazel advises clients on all aspects of patent strategy, including coordination of related patents and patent applications worldwide, interactions between drafting, prosecution and opposition matters, and assessment of how patent portfolio can be strengthened in view of a client's business goals.
Senior Manager, International Tax Services, EY
Mark is a Senior Manager at EY, currently working as a UK tax advisor in their international tax team. Mark started with EY working in the Cambridge office, assisting a broad range of companies in the Life Sciences sector, from start-ups to established business, across a wide range of Corporation Tax matters. He now works out of Birmingham and London and works with a number of multinational companies, continuing to assist across a broad range of Corporation Tax issues, but with a particular focus on IP structuring and tax efficient financing.
Mark continues to work primarily in the Life Sciences sector, with his current client portfolio consisting primarily of large multinationals and including both UK and non-UK headquartered groups. He also plays an active role in the EY Patent Box network, ensuring his clients and the wider firm can keep on-top of the recently evolving legislation.
Dr Dave Gervais
Innovation Lead, Porton BioPharma
David is Innovation Lead at Porton Biopharma Ltd and focusses on process and analytical development of enzymes and biologics. Recently, he contributed to the CMC section for FDA licensure of PBL’s main product Erwinase®, an enzyme drug used to treat Acute Lymphoblastic Leukaemia (ALL). Prior to working at Porton Down, he worked on vaccines and monoclonal antibodies at Pfizer in Sandwich, UK, and Merck & Co in West Point, PA, USA.
David has over 22 years’ experience in vaccine R&D and in Bioprocess R&D, is named on several patents and has authored several publications in peer-reviewed journals. He holds a BS and MS degrees in Chemical Engineering from the University of Massachusetts, USA and the University of Virginia, USA respectively, and a PhD in Biological Sciences from Oxford Brookes University.
David is a Fellow of the Royal Society of Biology (FRSB) and is an editorial board member for the Journal of Chemical Technology and Biotechnology (JCTB, Wiley) and the World Journal of Microbiology and Biotechnology (Springer).
Partner, Confluence Tax
Colin is the founder and managing partner of Confluence Tax LLP, which is focussed solely on providing tax advice to biotechnology and technology companies. He specialises in venture capital schemes, R&D tax credits, patent box, share incentive and M&A transactions for those industries. He chairs the Finance and Tax Advisory Committee of the UK BioIndustry Association(BIA) and is regularly involved in consultation work with HM Treasury and HMRC.
Dr Vlad Hogenhuis
Senior Vice President and Head of Specialty Pharma Franchise, GlaxoSmithKline
Vlad joined GSK in December 2012 to lead the Cardiovascular, Metabolic and Neurosciences therapeutic areas and was appointed to his present role to lead Specialty Pharmaceuticals in March 2015. He is accountable for the launch and growth of GSK’s medicines in several therapeutic markets, comprising immuno-inflammation, oncology, cardiovascular and metabolic, neurosciences, infectious diseases and dermatology. In addition to strategic and commercial accountability for a number of marketed medicines, Vlad is also responsible for the integration of manufacturing and research in shaping effective product launches in therapy areas new to GSK.
Prior to GSK, he worked for 18 years in a variety of senior commercial and operational roles at Merck & Co, latterly serving as General Manager of Belgium and Luxemburg. Prior to this, he was Chief Marketing Officer for China, with P&L accountability for men’s health, women’s health and diabetes, and general manager for the Neuroscience, Dermatology and Ophthalmology category
Vlad has an MBA degree with Director’s List distinction from the Wharton School of Business and a Medical Degree Cum Laude from Leiden University in the Netherlands. He served as a National Institutes of Health Fellow in Medical Decision Making at New England Medical Centre in Boston, and as a Naval Lieutenant Surgeon in the Royal Dutch Navy aboard HMS Tydemann
Dr Sarah Howell
Chief Executive Officer, Arecor
Sarah is the CEO of Arecor, a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.
Sarah has extensive experience of leading successful drug development opportunities within both large pharma and small biotech across a range of product types and therapeutic areas.
Prior to joining Arecor in 2011, Sarah served in a number of leading roles in the pharmaceutical industry including most recently VP CMC and Technical Development at BTG, a leading UK specialty pharma company, and prior to this holding Senior roles at UCB-Celltech and GlaxoSmithKline.
Sarah has a PhD in Physical Organic Chemistry and a Bsc in Chemistry.
Professor Tim Hubbard
Head of Genome Analysis, Genomics England and Professor of Bioinformatics, Kings College
Tim is Head of the Department of Medical and Molecular Genetics at King's College London and Director of Bioinformatics for King's Health Partners. He is also Head of Genome Analysis at Genomics England. Until 2013 he was Head of Informatics at the Wellcome Trust Sanger Institute where he was one of the organisers of the sequencing of the human genome. In 1999 Tim co-founded the Ensembl project to analysis, organise and provide access to the human genome and from 2007 led the GENCODE project to annotate the structure of all human genes. He is also actively involved in efforts to improve data sharing in science and develop open access publishing resources.
Tim is a member of the cross funding agency Expert Advisory Board on Data Access (EAGDA) and is chair of the Advisory Board of Europe PubMedCentral.
Dr Peter Jackson
Executive Chairman, The AMR Centre
Peter is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past ten years, he has created six new companies targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services. Since 2015, Peter has been chair of the steering committee created to establish the UK’s translational R&D centre focused on antimicrobial resistance, the AMR Centre based at Alderley Park in Cheshire.
He has taken up the leadership role since its start-up in February 2016. AMRC is a cornerstone of the transatlantic CARB-X initiative, announced in July 2016, supported with $250 million from the US Government with further funding from the Wellcome Trust.
Alastair Kent OBE
Director, UK Genetic Alliance
Alastair joined Genetic Alliance UK over 20 years ago because he was excited by the challenge that new knowledge in genetics created - the idea that, for people affected by a genetic condition, yesterday's science fiction is tomorrow's clinical service improvement.
Trying to transform these possibilities into positive outcomes whilst reducing the potential for abuse is an incredible challenge, and Alastair feels incredibly privileged to work in this field.
Genetic Alliance UK is now a respected and authoritative voice for patients and families is something about which he feels pride in, and also a huge sense of responsibility. It is a challenge that excited Alastair on the first day he became aware of the impact of genetic disorders and which continues to excites him today
Head of Curation, Genomics England
Dr Chris Gardner
Partner, Consilium Strategic Communications
Chris has more than 15 years’ experience in strategic communications from across the healthcare sector and has worked with companies at all stages of development including for some of the world’s leading pharmaceutical and biotechnology companies. He has led communications strategies on multiple cross-border IPOs, private fundraisings and international M&A. His corporate communication experience includes extensive profile raising campaigns to support companies’ business objectives and crisis communication.
Chris was formerly a Director in the Life Sciences team at Citigate Dewe Rogerson where he worked from 2003 to 2015 and an Associate Director at former specialist bioscience communications consultancy, HCC De Facto. He has degrees in Biological Sciences and Psychology, a background in journalism and a PhD in molecular biology
Dr Daniel Mahony
Partner, Polar Capital Partners
Daniel is a portfolio manager at Polar Capital. He studied biochemistry at the University of Oxford and received his Ph.D. from the University of Cambridge. Daniel moved to California to work as a research scientist at Schering Plough Corporation (now Merck & Co.) in 1995 and made the transition into financial services in 1998, working for ING Barings in New York and Morgan Stanley in London as head of the European healthcare research team.
In 2007, he set up Polar Capital’s healthcare team. He has over 23 years of experience within global healthcare covering sectors including biotechnology, medical technology and healthcare services
Dr Trevor Marks
Director of Development, Porton BioPharma
Trevor has a degree in Biochemistry from Manchester University and a PhD in Environmental Biochemistry awarded from Thames Polytechnic. He joined the Public Health Laboratory Service Centre for Applied Microbiology and Research (PHLS CAMR) in 1979 and has gained extensive experience working in a number of roles including research, production, product and process development and project management.
Trevor managed the Process and Analytical Development Group in Public Health England (PHE) for over five years, and is now Director of Development at Porton Biopharma Limited. His team have provided extensive support to a number of mature pharmaceutical products in terms of product and process characterisation, in addition to developing new products from concept to clinical trial. He has supervised five PhD students and has been an external PhD examiner at four universities, as well being an author on over 50 publications
Chief Executive Officer and Founder, Quanta Dialysis Technologies
John is CEO of Quanta Dialysis Technologies, where he was both a founding board member and an original investor through NBGI Ventures. He had the belief and vision that the initial technology concept of a novel fluid management system could be transformed into a disruptive medical product addressing the unmet needs of the $73 billion global dialysis market by using innovation to empower patients and deliver better outcomes.
John’s career spans more than twenty years, with extensive international experience in building and growing successful healthcare companies as an executive manager, board member, private equity investor and corporate financier. He is currently a member of the i4i selection panel at the NHS National Institute for Health Research and an Advisory Board member of Digital Health Forum. In addition, he is a regular speaker and panellist at global medtech and investment conferences.
Prior to his role as CEO of Quanta, John was Investment Director at NBGI Ventures, where he was closely involved with a range of innovative medical technology companies in Europe and the US, both as a board member and an investor.
Secretary General, EuropaBio
Nathalie has spent 20 years working for the biotech industry at EU and national level.
Nathalie started working in the biotechnology and food policy area for the European Crop Protection Association in Brussels and then moved to Rome to work for Dompé Farmaceutici S.p.A and the Italian National Biotech Association, Assobiotec dealing with the implementation of European biotech legislation at national level.
Within EuropaBio, Nathalie has held the posts of External Relations Manager, Director for Strategic Policy, Director for Healthcare Biotech, Director for Agricultural Biotech sector and has been the Secretary General since 2010.
In the course of her career, Nathalie has focused on improving the awareness of the importance and benefits of biotechnology for society and has worked, together with the industry, regulators and stakeholders, towards developing a more supportive legislative framework and operating environment for the industry and related sectors.
In 2013, Nathalie won the Technovisionaries Women Innovation Award organised by Women &and Technologies® while in 2009, Nathalie and the Green Biotech Team at EuropaBio were presented with the Leadership and Excellence in Advancing Ag-Biotech and Food Issues Award.
Nathalie graduated with Honours in Biochemistry and Biotechnology from St Andrews University, Scotland.
Chief Executive Officer, RSA
Chris has over 25 years’ executive experience of international Life Sciences across pharmaceuticals, biotechnology, informatics and start-up sectors.
He started his scientific career at Glaxo in 1990, leading multiple in-house and collaborative research projects. He was also a pioneer in the introduction of industrial IT, process and automation solutions to meet the needs of drug discovery, dramatically improving the productivity and quality of research efforts worldwide. Leaving GSK in 2004 Chris moved into biotech and to Asia as Chief Operating Officer of MerLion Pharmaceuticals, a biotechnology company headquartered in Singapore. He was responsible for business planning, operations, business development, licensing, fundraising and M&A.
Returning to the UK in 2008 Chris became VP Corporate Development at IDBS a high-growth international software company focussed on improving R&D and Healthcare organisations through better access to complex data. He was also a non-exec director on the Board of the RSA Group. Chris has held a number of additional Boards, technology and advisory roles and remain active in drug discovery, as CSO of a 'virtual' biotech company.
Since joining RSA he has specialised in placing leading academics, C-level and senior executives in biotech and informatics organisations worldwide.
Chief Executive Officer, Calchan
Brenda is a founder and CEO of Calchan, a Biotech company specialising in new medicines for pain and inflammation. She was previously a founder of Convergence, sold to Biogen during 2015, and before that a founder of PowderMed, managing its inception through to its sale in 2006 and subsequent integration into Pfizer.
Brenda is an independent advisor and NED to a number of life science companies. She enjoys mentoring management teams embarking on the start of a new Biotech company
Dr Sam Fazeli
Head of Bloomberg Intelligence, EMEA and Senior Pharmaceutical Analyst, Bloomberg Industries
Sam is a senior analyst and the European head of Bloomberg Intelligence, a real-time, interactive industry research platform available on the Bloomberg Professional service at BI . He specialises in Global pharmaceuticals and biotechnology.
Sam has more than 17 years of experience conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Prior to joining Bloomberg Intelligence in 2010, he worked at Piper Jaffray as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Sam has been ranked a top analyst by the UK and Pan-European Extel surveys.
Sam received a PhD in pharmacology from the University of London and a bachelor of science degree from Cardiff University.
Dr David Rhodes
Deputy Director, Public Health England
David is Head of Business Development and Deputy Director at Public Health England (PHE). He occupied a similar role for PHE's predecessor bodies (Health Protection Agency, and prior to that the Centre for Applied Microbiology and Research, Porton Down). Originally a plant pathologist, David gained his PhD from the Queen’s University of Belfast, before spending a number of years in academic and industrial research at Washington State University and ICI. He was responsible for R&D targeting and North American technology licensing for Zeneca Agrochemicals, and later for various strategic marketing programmes for Syngenta in Europe, Africa and Middle East Region.
David is a Certified Licensing Professional with a long-standing interest in technology transfer. He was awarded the MBA Prize by Henley Management College for his work on valuation of intellectual property, and studied international marketing at INSEAD, France.
David is also a Board Member of Medilink South West, the regional life science industry network, and a Fellow of the Royal Society of Medicine and the Royal Society of Biology. The Business Development team he leads won the Impact Awards 2015 (for Contribution to Society) from RCUK and PraxisUnico
Dr Andy Richards CBE
Andy has an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia, and the Babraham Research Campus and is a Director of Ieso Digital Health, Silence Therapeutics plc, Cancer Research Technology (commercial arm of CR-UK), Cambridge Temperature Concepts, and Cambridge University Hospitals NHS Foundation Trust. He is an advisor to Cambridge Innovation Capital and the UCL Technology Fund.
His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience plc. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice.
Andy is also a founder member of the Cambridge Angels and a trustee of the British Science Association.
Dr Denise Scots-Knight
Chief Executive Officer and Co-Founder, Mereo BioPharma
Denise is the CEO and a board member of Mereo Biopharma (MPH), a biopharmaceutical company focussed on rare and speciality diseases which she co-founded in 2015. Mereo has raised £90 million since July 2015 and is listed on the AIM market of the London Stock Exchange. Prior to Mereo, she was Managing Director and Head of the Life Science investment team at Nomura subsequently leading Phase4 Partners’ MBO from Nomura in 2010 and becoming Phase4’s Managing Partner. From 1997-1999 Denise was an Investment Manager at Rothschild Asset Management.
Prior to becoming a venture capitalist, she was in R&D management at Amersham and Fisons and a senior executive at Scientific Generics. She is a board member of OncoMed (OMED), and Albireo. She has served on many European and US private and public boards; including Idenix (until acquired by Merck for $3.5 billion).
Denise has a PhD and BSc (Hons) from Birmingham University and was a Fulbright scholar at UC Berkeley
Senior Press Manager, Science Media Centre
The Science Media Centre is an independent press office for the UK scientific community. It exists to help ensure that science and engineering in the UK national news is reported accurately and responsibly, particularly when a story has the potential for controversy. They give journalists the opportunity to speak to real experts, and actively encourage scientists to speak out when stories break. They also run regular press briefings, which allow scientists and engineers to set the news agenda on important subjects of public interest. Although independent, the SMC is unashamedly pro-science and has no public ‘brand’ to promote. This gives them the freedom to concentrate on what is important: responsible reporting of evidence-based science in the news.
Tom has degrees in Artificial Intelligence and Bioinformatics. He used to shout at the radio, throw things at the TV and fume over the headlines. In April 2008 he joined the Science Media Centre and since then has been calmer.
Dr Damien Smedley
Director of Genomic Interpretation and Associate Director of Bioinformatics, Genomics England
Damien is Director of Genomic Interpretation for Genomics England, overseeing the clinical analysis of the rare disease and cancer genomes emerging from the 100,000 Genomes Project. He is also a Senior Lecturer at Queen Mary University London where his research focusses on the use of phenotype data to obtain novel insights into disease causes and mechanisms. His team is involved in translational aspects for a number of projects such as the International Mouse Phenotyping Consortium (IMPC).
In collaboration with other members of the Monarch Initiative he has developed tools that utilise phenotype comparisons for candidate gene prioritization, particularly for next-gen sequence interpretation of rare disease patients as in the Exomiser software suite.
Dr Erin Sommers
Erin is a registered US patent attorney who focuses her practice on patent litigation and practice before the US Patent and Trademark Office (USPTO), primarily in the chemical and pharmaceutical areas. She has gained litigation experience at all stages of district court Abbreviated New Drug Application (ANDA) litigation and appellate practice before the Federal Circuit. She also assists clients with global management of their patent portfolios and prosecutes patent applications before the USPTO. She also represents clients before the Patent Trial and Appeal Board (PTAB) in post-grant proceedings.
Erin has significant experience in the field of organic chemistry, catalysis, organo-metallic synthesis, biochemistry, and cellular and molecular physiology
Chief Executive Officer, Shield Therapeutics
Carl has led the team that has raised close to £70 million since founding Shield Therapeutics plc. He has successfully developed Shield’s two leading assets, Feraccru® and PT20, recently resulting in the approval of Feraccru and completion of Shield’s IPO on the LSE.
With a life sciences background and an MBA from Henley, Carl has over 20 years of pharmaceutical industry experience, largely in the field of orphan and specialty medicines. He worked for United Therapeutics as a core member of the Company’s Remodulin™ commercialisation team as well as leading the company’s European operations for six years and in collaboration with key opinion leaders. He was responsible for and holds patents related to the development and commercialisation of Tyvaso™. A period at Encysive Pharmaceuticals followed, leading European commercial operations and delivering the successful launch of Thelin™. Encysive was acquired by Pfizer in 2008 and Carl established Shield Therapeutics.
A creative, lateral thinker with proven entrepreneurial flair and a clear record of delivering shareholder value. Carl’s key strengths include business leadership experience, creation and delivery of effective business strategy, as well as effective communication and relationship building capabilities
Dr Linda Summerton
Chief Executive Officer, Immodulon Therapies
Investment Director, Healthcare, Cambridge Innovation Capital
Robert joined CIC in January 2014 and heads up the healthcare investment team. After seven years working in hospital medicine, he joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche. Robert subsequently joined the Cambridge-based company Arakis and worked as Medical Director until its £106 million sale to Sosei Inc. Since that acquisition, he has been involved in a number of start-up companies, including founding the malaria-focused company Treague and being founding CEO of the University of Copenhagen spin-out Avilex Pharma.
In addition, he was part of the founding management team of KalVista which is developing the first plasma kallikrein inhibitor for diabetic macular edema working with its scientific founders from Harvard Medical School. His portfolio includes Congenica, Inivata, Cambridge Medical Robotics, Abcodia, Storm Therapeutics and Morphogen-IX.
Robert qualified in medicine from University College London. He is a member of the Royal College of Obstetricians and Gynecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an MPhil in Biostatistics from the University of Cambridge
Dr Ian Tomlinson
Chairman, Apollo Therapeutics and Stevenage Bioscience Catalyst and BIA Board
Ian is Chairman of the Board of the Stevenage Biosciences Catalyst, Chairman of the Investment Committee for Apollo Therapeutics, sits on the Board of the UK BioIndustry Association (BIA), and is part of the Major Awards Committee for the UK’s Biomedical Catalyst funding scheme.
Previously, Ian was Senior Vice President, Head of Worldwide Business Development and Head of Biopharm R&D at GSK. In his Worldwide Business Development role, Ian had global responsibility for all Pharmaceutical R&D related business development activities, including acquisitions, in- and out-licensing and collaborations. In his Biopharm R&D role, he combined the resources and development expertise of a large pharmaceutical company with the entrepreneurial spirit of a smaller biotech organisation, bringing early research, late-stage biopharm development and manufacturing expertise into one organisation. This ambitious integrated strategy led to a quadrupling of GSK's pipeline of clinical stage biopharmaceuticals from 10% in 2008 to 40% by 2015, including establishing a state-of-the-art cell and gene therapy platform within the Biopharm R&D organisation.
He joined GSK in January 2007 when it acquired Domantis Limited, a company he founded in 2000 with Sir Gregory Winter, for $454 million. Domantis was focused on the development of an entirely new class of drugs based on the smallest fragments of antibodies, known as domain antibodies, and had raised $83 million from a range of private and institutional investors by the time of acquisition. At Domantis, Ian was CSO and Executive Vice President, having direct responsibility for scientific strategy and UK operations but also played major role in investor and business development activities with investors such as MVM Limited and 3i and partners that included Imclone, Abbott and BMS.
Earlier in his career, Ian graduated from Trinity College, Cambridge, UK and then spent 11 years at the MRC Laboratory of Molecular Biology on the Addenbrookes Campus in Cambridge, where he initially worked on the completion of the sequencing and mapping of all human antibody genes, and later on engineering recombinant antibodies, during which time he was awarded the Max Perutz Prize and became a Junior Research Fellow of Trinity College.
Associate Director, Highly Specialised Technologies, National Institute for Health and Care Excellence
Sheela is currently the Associate Director of the Highly Specialised Technology program at NICE and is responsible for running the program to evaluate medicines and technologies for rare and ultra-rare conditions for commissioning in the NHS.
Prior to joining NICE, she was responsible for commissioning rare and ultra-orphan disease services in NHS England, where she delivered many improvements to these services by collaborating with industry, clinicians and patient groups. She held the position of national lead for lysosomal storage disorders and the Extra Corporeal Membrane (ECMO) service for adults working closely with ITU centres in England to manage bed pressures and patient needs. In addition, she successfully decommissioned failing services and seamlessly transferred the care of patients to better quality services.
As commissioner for the National Specialised Commissioning team, she held responsibility for the genetics and metabolic portfolio leading nationally for lysosomal storage disorders. In this role she delivered more efficient drug and homecare prices by running national tender exercises with the Department of Health, Commercial Medicines Unit. As a result of this, she was selected to sit on the Department of Health’s National Homecare Medicines Committee developing the national homecare standards.
Sheela has a passion for partnership working and believes that collaboration across the sector is the key to delivering high quality results. She is an adviser for the James Lind Alliance, a program that facilities identifying priorities for research. Sheela strives to ensure services for patients with rare conditions provide excellent quality and good outcomes in an efficient effective environment.
Professor S.S. Vasan
Senior Business Development Manager, Public Health England
Professor S.S. Vasan is PHE’s Senior Business Development Manager leading on innovation, international consultancy and global health, and performed this role for PHE’s predecessor body Health Protection Agency. A former McKinsey consultant, Rhodes Scholar and Professor of Preventive and Social Medicine, he has convened the public health track of the UK Bioscience Forum since 2013. Before joining Civil Service, he was Head of Public Health for Oxford University’s spin-out company Oxitec, and led the world’s first semi-field (and subsequently open-field) trials involving transgenic mosquitoes, and the progress of this technology from laboratory to field to combat chikungunya, dengue and zika. He has played a key role in numerous initiatives sponsored by international organisations (e.g. CBD, UNDP, WHO), and acted as expert reviewer/member to various governmental committees, regulatory and consultation exercises.
He obtained his doctorate from Trinity College, Oxford, and is a Fellow of Royal Society of Medicine, Royal Entomological Society and Royal Society for Public Health.
Dr Vasan represents PHE’s overseas commercial engagement in the UK InterLab Forum, and is a member of the Filovirus Task Group of the Medical Counter-Measures Consortium, the Global BSL4 Laboratories Network, and the India-UK Joint Working Group on Health including its Sub-Group on AMR.
Head of International Government Affairs and Public Policy, Vertex
Benjamin is head of international government affairs and public policy with Vertex Pharmaceuticals. Since joining the company in December 2013 Ben has responsibility for all government, policy and advocacy activities in support of Vertex’ international operations. Ben has over 20 years of experience in international government affairs and public policy in the life sciences sector, most recently with international and EU positions with Gilead Sciences, Johnson & Johnson and GSK.
Prior to the life sciences industry Ben worked as a consultant with EY Consulting in Brussels, Belgium. He started his career within the Chief Scientist’s Group, part of the UK’s Ministry of Agriculture Fisheries and Food. Ben holds Bachelor and Masters of Science Degrees from Southampton University and Imperial College respectively and has dual British-German nationality.
Dr Sukaina Virji
News Editor, SCRIP Intelligence
Sukaina has been reporting on all aspects of the pharmaceutical and biotechnology space since 2000. In her role as News Editor, she is tasked with ensuring Scrip continues to provide the business critical insight and analysis that its subscribers have relied on for more than 40 years. Sukaina's prior positions include Editor of the newsletter BioVenture View and the magazine BioPeople. She has a BSc in Applied Biochemistry from Brunel University and a PhD in biochemistry and molecular biology from University College London. Sukaina says she should have realised her calling was in the printed word rather than a petri dish when she found writing a 200-page thesis the least traumatic part of her academic career. Nevertheless, she soldiered on and completed a postdoc before cutting the cord with lab work. Based in the UK,
Sukaina is often asked to appear on TV and radio to commentate on business and R&D strategy relating to major news events in the pharma and biotech industry. She also chairs and takes part in panels and roundtables at industry events.
Dr Hakan Goker
Senior Investment Director, MS Ventures
Hakan is a senior investment director at Merck Ventures corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Hakan joined Merck Ventures in 2013 and previously was investing as a partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, he was instrumental in the creation, financing, and strategy of multiple biotechnology companies globally including Asceneuron (CH), Orphazyme (DK), Nimbus Discovery (US), F Star (NL), Bicycle Therapeutics (UK) and Nitec now Horizon Pharma (CH/US).
Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London.
Hakan is a board member of Asceneuron, Artios Pharma, Forendo, Raze Therapeutics, Tocopherx, Synaffix, and Storm Therapeutics.
Dr Harren Jhoti
President and Chief Executive Officer, Astex Pharmaceuticals
Harren co-founded Astex in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive. He also served as president and member of the Board of Directors of Astex Pharmaceuticals Inc., following the merger of Astex with SuperGen Inc., (subsequently renamed Astex Pharmaceuticals Inc.) in July 2011.
In 2015 Harren was elected a Fellow of the Academy of Medical Sciences in the UK. He was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as “Chemistry World Entrepreneur of the Year” for 2007.
He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Harren previously served as a non-executive director of Iconix Inc. and recently was on the board of the UK BioIndustry Association (BIA).
Before founding Astex in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (199 to 1999). Prior to Glaxo, Harren was a post-doctoral scientist at Oxford University. He received a BSc (Hons) in Biochemistry in 1985 and a PhD in Protein Crystallography from the University of London in 1989
Professor Neil Woodford
Head of AMRHAI Reference Unit, Public Health England and Visiting/Honorary Professor, Imperial College, UCL and QMUL
Professor Woodford is Head of the Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit at Public Health England. His Unit, based at Colindale, is a WHO Collaborating Centre.
Neil is an Honorary Professor at Queen Mary University of London and University College London, and is a Visiting Professor at Imperial College London where he also did his doctoral studies on Neisseria gonorrhoeae. He has worked on antimicrobial resistance for three decades and has co/authored over 350 publications and edited three books on this subject.
A Fellow of the Royal College of Pathologists, he has been an editor of the Journal of Antimicrobial Chemotherapy. Neil’s interests include antibiotic resistance mechanisms in bacterial pathogens, molecular analysis to track dissemination of resistance, and molecular diagnostics for rapid detection of resistance. He sits on many national and international committees relating to antimicrobial resistance, including serving as the scientific advisor to the Lord O’Neill Review.
Dr Jane Osbourn
Vice President Research and Development, MedImmune and Chair, BIA
Jane is VP Research and Development, MedImmune Cambridge, having joined MedImmune, formerly Cambridge Antibody Technology (CAT), in September 1993. Through a number of increasingly senior roles she originated several key publications and patents, and also made a significant contribution to the discovery and development of marketed drugs (Humira and Benlysta) and more than 40 clinical candidates.
Prior to joining CAT, Jane obtained a First Class degree in Natural Sciences (Biochemistry) from the University of Cambridge and completed a PhD at the John Innes Centre for Plant Science Research in Norwich. This was followed by a post-doctoral position at Rutgers University, New Jersey before moving into medical research through a British Heart Foundation Post-Doctoral Fellowship at the Department of Medicine at Addenbrooke's Hospital in Cambridge.
Jane is a director of the UK BioIndustry Association (BIA), a director of Babraham Bioscience Technologies and a member of the UK Medical Research Council Industry Grant Award Assessment Panel. She is an editor of both ‘Mab Journal’ and ‘Protein Engineering Design and Selection’. In 2010 Jane won the Institute of Directors’ East of England Business Woman of the Year Award.
Partner, PwC’s Strategy&, UK
Jo is a Partner leading the UK Pharma and Lifesciences Consulting Practice. She has 13 years of industry experience in the pharmaceuticals, energy, petrochemicals, and fast-moving consumer goods industries with BP and SmithKline Beecham where she held positions in the engineering, operations, IT, and commercial functions. Before joining PwC, she spent three years with Booz&Co, a strategic management consultancy where she focused on strategic issues in the pharmaceuticals and energy sectors.
Jo assists the pharma and life sciences sector in developing strategy and supporting deals. Her clients include Big Pharma, biotech, generics, OTC, contract manufacturers, contract research organisations, ministries of health, private equity and banks. She is a key author on PwC’s Pharma2020 thought leadership series. She is an advisory board member of MedCity.
Jo has an MBA from Warwick Business School and is a Chartered Engineer.
Dr David Cox
Healthcare Sales, Panmure Gordon
David is the Healthcare Specialist Salesperson at Panmure Gordon. Prior to joining Panmure in May 2016, David spent three years at a management and strategy consulting firm with a focus on European pharma companies. David completed multiple projects for a range of private and public pharma companies spanning corporate, commercial and research and development across multiple geographies and therapeutic areas. Before becoming a consultant David has held positions as a medicinal and process chemist at contract research organisations and within Big Pharma.
David holds a PhD in Organic Chemistry from the University of Cambridge and an MSci in Chemistry from the University of Bristol.
Sarah's daughter Millie was diagnosed with type 1 diabetes on New Year's Day 2002 when she was 11. Her grandfather had lost both his feet and had a kidney removed due to the condition, which he had had since 1960 when he was 32 so it wasn't a huge shock when Millie was diagnosed.
Over the years there have been some dangerous situations especially in mid-teens when Millie tried alcohol. Now 25, Millie has had an insulin pump for five years and there is no doubt that having it has improved her quality of life. However there have been several hospitalisations due to pump failure causing hypos. Like many young people with type 1 diabetes, Millie also has an eating disorder and suffers from depression and anxiety.
Dr Ken Macleod
Ken has been investing in the global life sciences sector for more than 15 years while at the investment firms SV Life Sciences, Paul Capital Advisors and Visium Asset Management. His responsibilities include sourcing, evaluating and negotiating healthcare structured finance opportunities. Prior to his role as an investor Ken had a strong operational background in the pharmaceutical and biotechnology industries where he held senior management positions over a 16-year career at Serono, Abbott Laboratories and Beecham Pharmaceuticals.
Ken received his PhD from the University of York and his B.Sc. from the University of Manchester. He currently sits on the Board of Phase Three Development Company S.à R.L. (P3D).